Federal Register Notice: FDA has determined the regulatory review period for Abbott’s Humira is 1,722 days for the extension of a patent which claims that human biological product. Humira (adalimumab) is indicated for reducing signs and symptoms, including major clinical response, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. To view this notice, click here.